Seattle Genetics Inc. (SGEN) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Seattle Genetics (SGEN) Weakness Creates Buying Opportunity, Says Analyst
May 2, 2014 1:28 PM EDTH.C. Wainwright reiterated a Buy rating on Seattle Genetics (NASDAQ: SGEN) with a price target of $65. Analyst Andrew S. Fein thinks recent macro weakness has opened a buying opportunity.
"Yesterday, SGEN reported 1Q14 financial results and gave an update on its development and clinical activities, which demonstrates that the underlying value of its... More
